版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
McKinsey
&Company
HealthcarePractice
Whattoexpectin
UShealthcarein2027andbeyond
Theeconomicpressureonthehealthcaresystemisrelentless.Valuewillaccruetoorganizationsthatcanturnfinancialpressureintoincreasedproductivityandbetterpatientoutcomes.
byNehaPatelandShubhamSinghal
withAnkitJain
November2026
ThestormcontinuestopassthroughtheUShealthcaresystem.Thepressuresidentifiedinourseries
of"gatheringstorm"articles¹firstbecamevisibleinprovidereconomicsandhavesincemovedintopayer
marginsandpatientaffordability.AccordingtoMcKinseyanalysis,providerEBITDAfellto$241billionin
2022beforerecoveringto$350billionin2025,whilepayerEBITDAfellfrom$60billionin2022to$9billionin2025.Thisisnotauniformcycle:Asonesegmentrebounds,pressureisoftentransmittedtoanother
throughreimbursement,pricing,utilization,orcoverage.
Theforcessustainingthatpressurearestructural.The2026USfederaldeficitisforecastat$1.9tillion,or5.8percentofGDP,andUSdebthascrossed$40trillion,constrainingfiscalflexibilityevenashealthcarespendingrises.3Healthcaredeliveryproductivitydeclinedabout1percentannuallyfrom2019to2025,
comparedwith2percentgrowthinthebroaderprivateeconomy.Meanwhile,nationalhealthexpenditures(NHE)percapitaroseroughly3.5timesfrom2000to2025,yethealthylifeexpectancyimprovedbyonlyeightmonths.5Thesystemisspendingsubstantiallymorewithoutacommensurateincreaseinhealthylife.
Industryeconomicsarelikelytoremaindepressedrelativetotheirprepandemiclevel.EBITDArepresented10.9percentofNHEin2019comparedwith9.6percentin2025.WeprojectnominalEBITDAgrowthinthecomingyears,butthatshouldnotbemistakenforarestorationofhistoricaleconomics.
Theoutlookinthisreportassumesmaterialmanagementaction.Forproviders,marginscouldpotentiallyincreaseby50basispointsofincrementalreimbursementfrompayersandbyupto100basispoints
fromproductivitygainsandtechnology-enabledoperatingredesign.Forpayers,portfolioshifts,productoptimization,andselectiveexitscouldcontributeupto200basispointsofmarginimprovement.Forbothprovidersandpayers,thesewouldbesizablenetimprovementsdespitecontinuingchallenges.Butwithoutmanagementaction,theunderlyingtrajectoryshowninourprojectionswouldbeweaker.
Valuewillcontinuetomigratetowardbusinessmodelsthatenablecaredeliveryinlower-costsettingsor
operatethesystemmoreefficiently.Ambulatorysurgerycenter(ASC)EBITDAisprojectedtogrow6.7
percentannuallyfrom2025to2030versus3.7percentforhospitals.Duringthesameperiod,specialty
pharmacydrugspendingisprojectedtogrow9.6percentannuallyversus7.0percentfortraditionaldrugspending,⁶whileapplicationsofAlareexpectedtoshifttowardsoftware,platforms,data,andtechnology-enabledservices.UShealthcareisnotreturningtoitsoldequilibrium;valuewillaccruetotheorganizationsthatfindwaystoturnfinancialpressureintoincreasedproductivityandbetterpatientoutcomes.
Severalhealthcaresegmentsareexpectedtofacefinancialpressure
WeestimatethatoverallhealthcareEBITDA⁷willgrow7percentannuallyfrom2025to2030(Exhibit1).
Butthetrajectorywillbeuneven.EBITDAgrowthisexpectedtoslowto4percentannuallythrough2027asdisenrollmentfromAffordableCareAct(ACA)policiesandMedicaidpolicychangesweighonpayerandprovidereconomicsbeforeacceleratingto9percentannuallyfrom2027to2030.Healthcareservicesandtechnology(HST)andpharmacyservicesshouldseerelativelysteadygrowththroughtheperiod.Providergrowthisweightedtowardthelatterhalfofthedecade,whilepayerEBITDAisprojectedtorecoverfromadepressed2025base.
1"ThegatheringstorminUShealthcare,"McKinsey,accessedOctober10,2026.
2ThefindingscitedinthisarticlearebasedonMcKinsey'sannuallyupdatedhealthcarevaluepoolmodel.
3Thebudgetandeconomicoutlook:2026to2036,CongressionalBudgetOffice,updatedMarch24,2026.
4"Privatecommunityhospitalslaborproductivity"USBureauofLaborStatistics,August26,2026;"TableA.Productivity,output,andinputsintheprivatenonfarmbusinessandprivatebusinesssectorsforselectedperiods,1987-2025,"USBureauofLaborStatistics,updatedMarch19,2026.
5"Nationalhealthexpendituredata,"CMS.gov,updatedSeptember22,2025;"Health,UnitedStates,"CDC,updatedFebruary27,2025.6AdamJ.Fein,2026economicreportonU.S.pharmaciesandpharmacybenefitmanagers,DrugChannelsInstituteteam,March2026.
7Inthisarticle,weuseEBITDAasameasureofeconomichealthoftheindustry.OnlyafractionofEBITDAtranslatesintonetincomefor
theindustry,withnetincomemarginsinthelowsingledigitsafteraccountingforinterest,taxes,depreciation,andamortization.EBITDA
retumsenableorganizationstogeneratethecapitalnecessaryforinvestments,includingthoseforenhancingcapacityandaccess,buildingcapabilitiestooffernewandimprovedtreatmentsandpatientexperience,andfacilitatingtechnology-driventransformation.
WhattoexpectinUShealthcarein2027andbeyond2
Exhibit1
Mostsegmentsarelikelytogrowmorethan5percentperannumby2030.
DistributionofprojectedhealthcareEBITDAacrosshealthcaresegments,2030,$billion
2025-30CAGR,%<00-5-10>10
Individual¹一
Medicaid—
Medicare²—
Coreadminservices
Group
Hospitals
Logistics
andsupply
chain
PBMs
and
PBAs⁸
Phemaand
biotech
Paymertservices
Specialtypharmacy
nd
irfiusionservices
Crical
Services
Broker
solutions
Consutinq
nonacute
Duals
Data
analytics
Office-basedprysicians
Sofware
ad
platformB
Virtualhealthcare
Otherprofessionals
Medicalproducs
Distributors
Diagnostic
Postacute
Ancillary
Traditional
dispensers⁵
HBS
Payers
85
Providers
438
ServicesPharmacyandtechservices
123138
Manufacturers
357
Includesindividualcoveragehealthreimbursementarrangements.2lncludesMedicarePartC,Medicaresupplementinsurance,andMedicarePartD.
Fixed-benefitandsupplemental.Pharmacybenefitmanagersandadministrators(nondispensingsourcesofvaluel.5includeretailandmailpharmacies.Source:McKinseyValuePoolsModel
McKinsey&Company
WhattoexpectinUShealthcarein2027andbeyond3
WhattoexpectinUShealthcarein2027andbeyond4
Payers
Payerprofitabilityhasundergoneahistoricreset.TotalEBITDAfellfromabout$62billionin2023to
$33billionin2024andto$9billionin2025asgrowthinmedicalcostsoutpacedpremiumpricingand
governmentrateupdates.Theyear2025wasthetrough;majorrisk-bearingsegmentscollectivelyturnedunprofitableforthefirsttimethisdecade.EBITDAcouldincreasetoabout$84.5billionby2030,althoughtherecoverywillbeuneven.
Thedeteriorationreflectshigherutilization,risingproviderunitcosts,GLP-1andspecialtypharmacygrowth,andbehavioralhealthdemand,compoundedbyadverseshiftsinriskpoolsacrossMedicaidandtheACA
andbyhigher-than-anticipatedout-of-networkpaymentawardsundertheNoSurprisesAct'sindependentdisputeresolutionprocess.8Theyear2026marksaninflectionpointaspayerpricingbeginstocatchup
withmedical-costtrends,supportedbysubstantialgroupandACApremiumincreasesandcontinued
benefitandproductoptimization.MoremeaningfulEBITDAimprovementshouldemergein2028astheseactionsflowthrough.
Weexpectthegroupcommercialsegmenttoleadtherecovery,supportedbyimprovingfullyinsured
underwritingandcontinuedgrowthinhigher-marginadministrative-services-only(ASO)andstop-loss
businesses.TheMedicareAdvantage(MA)segmentshouldalsograduallyrecoverfrom2025losses,
althoughmarginsmayremainbelowhistoricallevels.Incontrast,ACAandMedicaidsegmentsfacethe
greatestdisruptionsinenrollmentandriskpools,drivenbysubsidyexpirationforACAandeligibilitychangesforMedicaid.
Overall,thesubsector'srecoverywilldependonpricingdiscipline,businessmix,scale,andmedical-cost
management,withdiversifiedearningsstreamsprovidinggreaterresilienceasindustryprofitabilityrebuildsthrough2030.Atthesametime,priceincreasesruntheriskoffurtherenrollmentdecline,particularlyinthesmallgroupcategory.
Providers
ProviderEBITDAcontinuedtorecoverfromalowof$241billionin2022to$322billionin2024and$369billionin2025aspatientvolumesnormalized,reimbursementratesimproved,andlaborandinflationarypressuresmoderated.Still,profitabilityremainsbelowprepandemiclevels.Therecoverywillbeuneven.EBITDAwillfacerenewedpressurethrough2027asACAsubsidyexpirationandMedicaiddisenrollmentincreasethenumberofthosewithoutinsuranceandtherateofuncompensatedcare,withadditional
downsidefrompotentialMedicaidreimbursementchangesandsite-neutralitypolicies.
Beyond2027,marginsshouldgraduallyimproveascommercialenrollmentrecovers,annualrateincreasesflowthrough,andproviderscapturefurtheroperatingefficiencies.ButreductionsinMedicaidstate-
directedpaymentscouldtempertherecovery.ProviderEBITDAcontinuestoshifttowardlower-cost
ambulatoryandhome-basedsettings.ASCsaregaininghigher-acuityproceduresaspayerssteercare
towardlower-costsitesandastheCentersforMedicare&MedicaidServices(CMS)expandstheASC
CoveredProceduresList,broadeningtherangeofprocedureseligibletomigratefromhospitalsettings.Inpostacutesettings,homehealth,hospice,andassistedlivingfacilities(ALFs)areexpectedtoseeincreaseddemandfromagingdemographicsandpatientpreferenceforhome-basedcare.Withinphysicianpractices,specialtyandancillary-rich(forexample,labandimagingservices)modelsareemergingasgrowthengines,whiletraditionalprimarycareremainsrelativelylower-margin.Together,theseshiftsarereducingthe
relativecontributionoftraditionalacuteandinstitutionalsettingstooverallproviderEBITDA.
BudgetOffice,June15,2026.
8CBOBlog,"AcallfornewresearchontheNoSurprisesAct"blogentrybyJessicaHale,TamaraHayford,andDariaPelech,Congressional
WhattoexpectinUShealthcarein2027andbeyond5
Healthcareservicesandtechnology
HSTisexpectedtoremainthefastest-growingsubsectorinhealthcare.Weestimatethatrevenuewillgrow7to8percentandEBITDA9to10percentannually,increasingrevenuepoolstomorethan$500billion
andEBITDApoolstomorethan$120billionby2030.Underlyingthatgrowthisashiftinmixfromlegacy
outsourcedservicestowarddataandanalytics,softwareplatforms,andtechnology-enabledservices.
TherapidemergenceofAlisacceleratingthisbroadertrendandisexpectedtoincreasethevariabilityof
revenueandEBITDAgrowthoutcomesforHSTcompanies.HSTplayersfacearisingdisplacementriskif
theydonotadoptAlatscale;ontheotherhand,therearemarginexpansionopportunitiesforthosethatdo.9
Healthcarehashistoricallystruggledtoconverttechnologyintoproductivity,withoutputperemployeeinhealthcaredeliveryessentiallyflatoverthepast25yearswhileotherservicesindustriesadvancedmorethan50percentoverthesameperiod.0EarlysignssuggestAlmaybreakthatpatternbecauseadoptionhasmovedwellbeyondexperimentationacrossmanyhealthcareorganizationsandagrowingshareof
implementersarebeginningtoshowmeasurablepositivereturns.MostconsequentiallyforHST,morethanthree-quartersofhealthcareorganizationssaytheyintendtopartnerorbuyratherthanbuildthecapabilitiesneededtocapturevaluefromAI."Thiscouldcreatesubstantialdemandforvendorsabletosupplyscarcetalent,infrastructure,changemanagement,andexecutionatpace.
CompetitionintheHSTsegmentisevolvingasnewAl-nativechallengersemergewhobringspeed,
focus,andlower-costdeliverymodels.Atthesametime,incumbentHSTplayerswhohavedurabledata
andworkflowadvantagesarestartingtoreimaginethoseworkflowsinanAlworld,potentiallyleadingto
greateroperationalefficienciesandcostsavings.Thecombinationofmorecompetitionandincumbents'
advantagesiscontributingtoacceleratedoutsourcingasprovidersandpayerslooktoHSTvendorsasawaytoaugmenttheirownworkflowsandbenefitfromthecostsavingspotentialofAI.AscompetitionbetweentheseHSTincumbentsandinnovatorsincreases,legacyservices-basedsegmentswithinHST,suchascoreadministrativeservices,mayseepricepressureoverthenextthreetofiveyearsasvendorscompetetoearnshare.
Pharmacyservices
Pharmacyremainsoneofhealthcare'sfastest-growingsegments.Weestimatepharmacyvaluechain
EBITDAwillgrowfrom$97billionin2025to$138billionby2030,roughly7percentannually,withspecialtypharmacyandinfusionservicesaccountingfornearlyhalfofthe2030pool.Hospital-ownedspecialty
pharmacyisthefastest-growingsegment,expandingabout15percentannually,whilephysicianofficeandhomeinfusionarecapturinganincreasingshareofcareastreatmentshiftsacrosssites.
Awaveofregulatoryaction-includingpharmacybenefitmanager(PBM)transparencyprovisions(for
example,theConsolidatedAppropriationsAct,2026),Medicaredrugpricenegotiations,MostFavored
Nation(MFN)pricing,arevised340BDrugPricingProgramrebatepilot,andsite-neutralpayment
reforms-isreshapingeconomicsacrossthepharmacyvaluechain.Meanwhile,PBMreformsareincreasingpressureontraditionalrebate-andspread-basedmarginsandareacceleratingashifttowardfee-based
compensationmodels.
Theresultisasectorinwhichaggregategrowthremainsresilientbutinwhichvalueisbeingredistributedacrossstakeholdersandsitesofcare.Competitiveadvantagewillincreasinglydependontheabilityto
manageclinicaloutcomes,adaptcontractingmodels,anddemonstratedifferentiatedcapabilitiesbeyondtraditionalformularyandutilization-managementlevers.
Let'slookmorecloselyatsubsectorperformance.
9HSTprojectionsincorporatetheexpectedimpactofAl.ProjectionsforothersegmentsdonotyetexplicitlyeflectAl-drivenproductivityormargineffectsandwillbeupdatedinafutureedition.
10McKinseyanalysisofthepercentchangeinrealgrossoutputperful-time-equivalentemployee,1998-2023,chained(2017)dolaseries,fromtheUSBureauofEconomicAnalysis.
WhattoexpectinUShealthcarein2027andbeyond6
Payers:Pricingbeginstocatchuptomedical-costtrendsafterahistoricmarginsqueeze,settingupanunevenrecovery
TotalEBITDAdeclinedfrom$32billionin2024toabout$9billionin2025.Acrossthemajorpayersegments(group,individual,andgovernment),EBITDAfellfromabout$51billionin2023and$20billionin2024to
roughly-$4billionin2025.Thisisthefirsttimethisdecadethatthebusinessofbearingmedicalriskhas
collectivelygeneratednegativeEBITDA.However,thedeclineinthepayermarkethasbeenuneven,markedbygrowingdivergenceacrosssegmentsbasedonsizeandtypeofcarrier.
Thesharpdeteriorationreflectselevatedmedical-costinflationflowingthroughpayerclaimsfasterthan
premiumpricingandgovernmentratescanadjust.Highermedicalutilization,risingproviderunitcosts,
increasedGLP-1andspecialtypharmacyutilization,andbehavioralhealthdemandaccountedforthegap
betweenpremiumgrowthandclaimscosts,leadingtomargincompressionacrossrisk-bearingbusinesses.Coverageshiftscompoundedthepressure.Medicaidredeterminationleftasmaller,higher-acuityretainedpopulation,whilemembersmovingfromMedicaidintotheACAexchangesincreasedriskpoolmorbidityandcontributedtothesharpdeteriorationinindividual-marketeconomics.
Performancealsodivergedsharplybypayerscaleandbusinessmixin2025:Small-sizepayers(thosewith
lessthan100,000members)have5percentlessaverageEBITDAmarginthanlarge-sizepayers(thosewithmorethan500,000).Diversifiednationalpayersremainedprofitableintheircorepayerbusinessesin2025,whilenationalswithnarrowportfoliosgeneratedonlymodestearnings;otherpayerscollectivelyrecordedlosses(Exhibit2).Inadditiontoperformingbetterinthecorepayerbusiness,diversifiednationalsalsohavelowerexposuretothecorepayerbusinessoverall(Exhibit3).Together,theseresultspointtotherecent
advantagesofscaleandadiversifiedearningsbaseinnavigatingperiodsofelevatedpressureonmedicalcosts.
Exhibit2
Payerprofitabilityhasdivergedsharply,withdiversifiednationalscapturingthemajorityofcorepayerearnings.
CorepayerbusinessEBITDAbypayertype,2025,$billion
Diversifiednationals²
Narrowportfolionationals³1.2
Allotherpayers-12.2
PayersegmentEBITDAforeachpayerisestimatedbasedonreportedoperatingmarginandD8AexpensesFiguresexcludestop-los,indvidualcoveragehealthreimbursementarrangements,thefixed-benefitandsupplementalsegment,andancillarysegments.
²UnitedHealthGroup,Elevance,Cigna,andAetna.
Centene,Humana,andMolina.
Source:NationalAssociationofInsuranceCommissionersfilings;McKinseyValuePoolsModel
McKinsey&Company
"McKinseyQ22026USGenAIHealthcareSurvey,July2026,n=120(40payers,40providers,and40HSTplayers).
Exhibit3
Nationalplayershavediversifiedearnings,withlower-marginpayer
businessescontributingabout20to60percentofoperatingincome.
Shareofoperatingincomefrompayerlines,2025,%
Elevance
UnitedHealthGroup
Cigna
Aetna20
McKinsey&Company
Entering2026,payerpricingbegantocatchupwithelevatedmedical-costtrends,animportantinflectionpointafterseveralyearsinwhichclaimsgrowthoutpacedrateactions.Early2026payerresultsconfirmthatpricingandbenefitactionsaretranslatingintomedical-costperformanceimprovements.CommercialandACAcarriersincreasedpremiumssubstantially,whileimprovedMAfundingandcontinuedproduct
andbenefitoptimizationprovidedadditionalsupport.However,EBITDAresultsareexpectedtolagbehindbecausehigherrateswillbeoffsetbybuy-downsandenrollmentandriskpoolpressurespersist.More
meaningfulEBITDArecoveryisexpectedtoemergefrom2028onward.
Theoutlookalsovariessubstantiallybysegment(Exhibit4).Commercialfullyinsuredgroupsegment
andMAsegmentmarginsareexpectedtoimprovegraduallythrough2030butarelikelytoremainbelow
historicallevelsamidpersistentpressureonmedicalcostsandslowingmembership.Theindividualand
MedicaidsegmentsfacethesharpestenrollmentresetsfromACAsubsidyexpirationandMedicaideligibilitychanges.Theirrecoverypathsalsodiverge:TheACAsegmentislikelytomaintainmodestlypositivemarginsthroughaggressiverepricing,whileMedicaidrecoveryislikelytoremainslowergivenrate-settinglagsandfurthereligibility-relatedpressurein2027-28.
WhattoexpectinUShealthcarein2027andbeyond7
WhattoexpectinUShealthcarein2027andbeyond8
Exhibit4
By2030,mostlinesofpayerbusinessesareexpectedtorecoverfrom2025lows,thoughmarginsmaystaybelowprepandemiclevels.
DistributionofprojectedhealthcareEBITDAacrosspayersegments,2030,$billion
Hospitalindemnity
-
Long-
2025-30CAGR,%<00-<55-10>10
Largegroup
IQRA°
Duaks
Dental
Accident
and
AD&D
Indviduad
Stup-loss
Short-
term
disability
Vision
Medicaid
Admristraltiveservicesory
Critical
illness
MAandMAPD⁵
Long-
term
disability
Thind-partyadministralor
Prescipiondug
Smallgroup
Medicaresupplement
termcare
Group
Individual
Government
Ancillary
28
8
33
8Fixed-
benefitandsupplemental
2
IExcludesivestmentincome.Excludethird-partyadministrator.Ilndividualcoveragehealthreimbursementarangement.ExcludesICHRA5MedicareAdvan-tageandMedicareAdvantagePrescriptionDrug.5Accidentaldeathanddismemberment.
Source:McKinseyValuePoolsModel
McKinsey&Company
Groupinsurance
Groupinsuranceisakeydriverofthepayerrecovery.EBITDAfelltoabout$3billionin2025,butitis
expectedtoreboundtoabout$28billionby2030(aboutone-thirdofpayerEBITDA)assustainedrate
actionsbegintocatchupwithelevatedmedical-costtrendsandimproveunderwritingperformance.Fullyinsuredmarginsshouldrecovergraduallyaspremiumgrowthoutpacesclaimsgrowth.Butpersistent
WhattoexpectinUShealthcarein2027andbeyond9
utilizationandunitcostpressuresaswellascontinuedmigrationtowardalternativefundingarrangements,suchaslevel-fundedinsurance,arelikelytokeepprofitabilitybelowhistoricallevels.
Withinfullyinsuredlargeandsmallgroupsegments,revenuepermemberperyear(PMPY)isexpectedto
rise9to12percentin2026beforenormalizingto5to8percentoverthelongertermaspayerspushthroughrateincreasestocatchupwithelevatedmedicalcosts.Evenwiththesepricingactions,returningfullyinsuredmarginstothehistorical3to4percentrangewillremainchallenging.Inthesmallgroupsegment,acceleratingcoveragedeclinesandthemigrationofhealthieremployerstowardalternativefundingarrangementscouldleaveasmaller,higher-acuityfullyinsuredpool,sustainingupwardpressureonclaimstrends.
Thelargegroupsegmentfacesasimilarstructuralshiftasemployersincreasinglymovetowardself-insuredandotheralternative-fundedproducts,reducingthefullyinsuredriskpool.Together,theseshiftsincreaserelianceonsustainedpricingdisciplineaswellasmoderationinutilizationandunitcosttrendstorestore
historicalprofitability.Scaleprovidessomeprotectionbecauselargercarriersarebetterpositionedtoabsorbunderwritingvolatilityandspreadadministrativecosts,whilesmallercarriersfaceamoredifficultpathbacktoprofitability.
Self-insuredmembership
Self-insuredmembershipisexpectedtoincreaseabout1.0to1.5percentannually,withstrongergrowthfrom2027onwardasemployerscontinueshiftingfromfullyinsuredtoself-fundedmodelsandassomemembersdisenrolledfromMedicaidandtheACAmoveintoemployercoverage.Marginsarelikelytoholdsteadyat8to9percent,supportedbyattractiveeconomicsacrossASOadministrationandadjacentofferingssuchasstop-lossmodels.Withinthissegment,third-party-administratorenrollment,whichcurrentlyrepresentsabout26
percentoftotalASOmembership,isexpectedtoriseto30percentby2030,withrevenuePMPYgrowing1to2percentandEBITDArising6to7percentannuallyoverthe2025-30period.
ACAmarket
ACAmarginsdeclinedsharplyto-3.7percentin2025,promptingpayerstosecureapprovedpremium
increasesofabout26percentfor2026toaddresselevatedmedical-costtrendsandrestoreprofitability.However,theexpirationofenhancedsubsidiesintroducesanewheadwind:Enrollmenthasalreadydeclinedbyapproximately5.0millionpeoplein2026,withafurther3.5millionto4.0milliondropanticipatedin
2027.1²Ashealthierandmore-price-sensitivemembersdisproportionatelyexit,theremainingriskpool
islikelytobecomehigheracuity,requiringcontinuedrepricing.Afurther11percentpremiumincreaseis
projectedfor2027,helpingmarginsreturntoandremainmodestlypositivedespiteamateriallysmallerandhigher-costmembershipbase.
TheseactionsmakeACAoneoftheclearestexamplesofpayersproactivelyrepricingforanticipated
deterioration,reflectingbothunderlyingmedical-costtrendsandworseningriskpoolmorbidityfollowingsubsidyexpiration.Buy-downsareexpectedtooffsetaboutthreetofourpercentagepointsofpremiumgrowth,moderatingrealizedrevenuePMPYgrowth.Despitetheenrollmentreset,marginsarelikelyto
remainpositiveatroughly2to3percent,withrevenuePMPYgrowthnormalizingto4to5percentoverthelongerterm.
MedicareAdvantage
TheMAsegmententered2025understress.Marginswerepressuredin2024,approachingbreakeven
overall,andslippedintooutrightlossesin2025.EBITDAisexpectedtorecoverfromroughly-$3.4billionin2025toabout$11billionby2030,stabilizingneara2percentlong-termtarget-thoughstillbelowhistoricallevels.Theturnhingesonpolicyandpricing:CMS'sestimatedaverageMApaymentupdateincreasedfrom3.70percentin2025to5.06percentin20263;2026isthefinalyearoftheCMS-HCCVersion28risk
adjustmentmodelphase-in;andtheInflationReductionAct'sPartDredesigncontinuestoweighonPartDstand-aloneandMAprescriptiondrugplaneconomics.
12"Theaveragemarketplacedeductiblegrewbyabout$1,000perpersonin2026,withmoreenrollesshiftingtohigher-deductibleplansasenhancedtaxcreditsexpired,"KFF,May19,2026.
3“2025MedicareAdvantageandPartDrateannouncement,"CMS.gov,April1,2024;“2026MedicareAdvantageandPartDrateannouncement,"CMS.gov,April7,2025.
Persistentfundingandutilizationpressuresaredrivingpayerstowardpricingactions,benefitredesign,productoptimization,andmoreselectivemarketparticipation,supportingmarginrecoverywhile
moderatingenrollmentgrowth.Scaleremainsanadvantage,withlargerMAcarriersbetterpositionedtoabsorbvolatilityandoptimizeproductsacrossmarkets.
Overthelongerterm,utilizationstabilization,improvedfunding,andcontinuedproductoptimizationshouldsupport100to250basispointsofmarginimprovementfromdepressed2025levels,bringingmarginstoroughly2percentby2030.MApenetrationisexpectedtostabilizeat50to55percentoftotalMedicarebeneficiaries,withmembershipgrowthfallingfrom7percentannuallyinthe2019-25periodtoabout3
to4percentannuallygoingforward,accordingtoCongressionalBudgetOfficeestimates.CMSpaymentupdates,alongwithcontinuedriskscoregrowth,shouldsupportnear-termMArevenuegrowth,with
revenuePMPYprojectedtogrowabout7percentin2026beforefallingto4to5percentannuallyasthesefactorsnormalize.
Medicaid
Medicaidenrollmentdeclinedbytwomilliontothreemillionmembersin2024-25aspublichealth
emergencymeasurescontinuedtounwind,accor
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 医学遗传学题库及参考答案
- 2026年演员资格证题库及答案
- 采购经理供应商评估指南
- 2026年锅炉工艺模拟考试卷(含答案)
- 2026年基础生命支持技能掌握程度测试模拟试题(含答案)
- 2026年投会计教育模拟试题及答案
- 2026年基层护士三基模拟试题(含答案)
- 2026年工程测量工(高级)理论知识复习题(含答案)
- 2026年勘察类模拟考试卷(含答案)
- 2026年信息技术应用与创新实践模拟试题及答案
- 2022建筑电气防火检测技术规程
- 塑胶-塑胶件控制计划
- DBJT15-189-2020 广东省公共厕所设计标准
- 蛋糕店食品安全管理制度
- 大数据与财务管理专业教学标准(高等职业教育本科)2025修订
- DZ/T 0153-2014物化探工程测量规范
- T/CECS 10201-2022丁基橡胶自粘防水卷材
- 易货师专业知识培训课件
- 《欧盟介绍演讲》课件
- 消毒管理办法
- JBT 7047-2006 滚动轴承 深沟球轴承振动(加速度)技术条件
评论
0/150
提交评论